DNA analyses. Selection of the SNPs was based on the data available from HapMap project's website (13) . Six SNPs were chosen from different haplotype blocks to cover the genomic region of PPARD. SNPs were genotyped using the TaqMan Allelic Discrimination Assays (Applied Biosystems, Foster City, CA) as previously described (10) . Sequence information for oligonucleotide primers and probes is available from the authors. Quantitative PCR. Total RNA from subcutaneous adipose tissue of 87 offspring of Finnish patients with type 2 diabetes was isolated using Trizol reagent (Invitrogen) and Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany). Total RNA was DNase treated using a DNA-free kit (Ambion) and transcribed to cDNA using random primers and a high-capacity cDNA archive kit (Applied Biosystems). Quantitative RT-PCRs were performed in a 7500 Real-Time PCR System (Applied Biosystems) using 6 ng (RNA equivalents) of cDNA as template, gene-specific primers, and probes (sequence information is available upon request). PPAR-␦ (Hs00602622_m1) expressions were normalized to large ribosomal protein P0 (RPLP0; Hs99999902_m1) using standard curve method. Statistical analysis. We used the SPSS program (version 11.0 for Windows; SPSS, Chicago, IL) in data analysis and gave the results as either means Ϯ SD or percentages. Non-normally distributed parameters were logarithmically transformed. Two-tailed Student's t test, nonparametric, 2 , and Fisher's exact tests were used to compare variables between the groups, when appropriate. Logistic regression analysis was used to evaluate the effect of SNPs on the conversion to diabetes. Linkage disequilibrium (LD) statistics were calculated and haplotype blocks were visualized by using Haploview software (14) (available at http://www.broad.mit.edu/mpg/haploview/). Haplotype estimation from unrelated individuals was performed by using SNPHAP (available at http://www-gene.cimr.cam.ac.uk/clayton/software/).
RESULTS
The LD statistics (DЈ, r 2 ) and the minor allele frequencies of the SNPs of PPARD are shown in Fig. 1 . As the number of homozygous subjects for the rare allele of each SNP was small, they were combined with heterozygous subjects in all statistical analyses. Frequencies of genotypes of four SNPs of PPARD followed the Hardy-Weinberg expectations. However, genotype distributions of rs2076167 and rs1053049 deviated from the Hardy-Weinberg equilibrium (P Ͻ 0.025 and Ͻ0.015, respectively). No genotyping errors were found. Despite that, SNPs rs2076167 and rs1053049 (both in tight LD with rs3734254; inter-SNP DЈ Ͼ 0.98, r 2 Ͼ 0.8; Fig. 1 ) were excluded from further statistical analyses.
The association of four SNPs of PPARD with the conversion to type 2 diabetes is presented in Table 1 . Because rs6902123 had an interaction with sex in its effect on the conversion to diabetes (logistic regression analysis, P ϭ 0.008), we show the results separately for men and women. The C allele of rs6902123 was more frequent among women who converted to diabetes compared with women who did not. In logistic regression analysis, the presence of the C allele in women increased the risk for the conversion to diabetes by 2.47-fold (95% CI 1.32-4.63; Next, we investigated whether the SNPs of PPARD further increased the risk for the conversion to diabetes in carriers of the Gly482Ser (rs8192687) substitution of PGC-1A, which was previously shown to increase the risk of diabetes in participants of the STOP-NIDDM trial (15) . To this aim, study participants were classified into three groups: subjects having both the nonrisk genotype of PPARD and the nonrisk genotype of PGC-1A (Gly482Gly) (the reference group), subjects with one risk allele of either PPARD or PGC-1A, and subjects possessing both the risk allele of PPARD and the 482Ser risk allele of PGC-1A. Subjects of the placebo group possessing both the 482Ser allele of PGC-1A and the C allele of two PPARD SNPs (rs6902123 and rs3734254) had a 2.56-and 2.15-fold higher risk for the conversion to type 2 diabetes compared with those having neither risk genotypes (Table 2 ). ORs varied from 2.30 to 2.92 after the adjustment for confounding factors. The presence of one risk allele (that of either PGC-1A or PPARD; Table 2 ) in subjects of the placebo group resulted in a 1.5 increase in the risk of diabetes, a finding similar to that observed earlier for the 482Ser allele of PGC-1A alone (15) . The simultaneous presence of the PPARD risk allele and the 482Ser allele of PGC-1A increased the risk up to 2.2-fold, suggesting an additive effect. Furthermore, carriers of one or both risk alleles of PPARD and PGC-1A benefited more from the intervention (acarbose) than did noncarriers.
In women, the simultaneous presence of the two risk genotypes (the Pro12Pro genotype of PPARG2 [rs1801282] and the C allele of rs6902123 of PPARD) increased the risk for the conversion from IGT to diabetes by 3.93-fold (95% CI 1.79 -8.63; P ϭ 0.001) compared with women having the protective genotypes (the 12Ala allele of PPARG2 and the TT genotype of rs6902123 of PPARD) (P ϭ 0.006 for the interaction between the combined genotypes and sex). Adjustment for confounding factors increased the risk to 5.06-fold (2.20 -11.60; P Ͻ 0.001). Other SNPs of PPARD, together with the Pro12Pro genotype of PPARG2, had no additive effect on the conversion to type 2 diabetes.
DISCUSSION
This is the first study demonstrating that an SNP rs6902123 of PPARD alone and in combination with the Pro12Ala polymorphism of PPARG2 and two SNPs (rs6902123 and rs3734254) of PPARD in combination with the Gly482Ser substitution of PGC-1A predicted the conversion from IGT to type 2 diabetes.
PPAR-␦ plays a prominent role in energy homeostasis. Overexpression of PPAR-␦ in skeletal muscle (3) and adipocytes (2) markedly increase fat catabolism in both tissues. Given the important role of FFAs in the development of type 2 diabetes (16), the upregulation of the oxidative phosphorylation pathway by PPAR-␦ is beneficial in alleviation of insulin resistance and adiposity (1). PPAR-␦ agonists increase glucose transport (5) and consequently decrease insulin and glucose levels (2,3). Therefore, variants in PPARD could potentially modify glucose metabolism. Indeed, we recently reported that SNPs of PPARD significantly modulated glucose uptake in skeletal muscle, measured by positron emission tomography (10) . In the present study, the C allele of rs6902123 increased the risk of diabetes by 2.5-fold. The association was observed only in women but not in men. This sex difference remains unexplained.
SNPs of PPARD also increased the effect of the *Adjustment for age, sex, smoking, weight at baseline, and weight change. †Statistically significant. (rs6902123 T/C; rs2016520 T/C; rs3734254 T/C) ϩ rs8192687 G/A genotypes were coded as (0) ϭ TT ϩ GG; (1) ϭ TT ϩ (GA ϩ AA) and (
Gly482Ser substitution of PGC-1A on the risk of type 2 diabetes. This is not surprising since PPAR-␦ appears to have a strong interaction with PGC-1␣ (2,7). Similarly to PGC-1␣ (7, 17) , PPAR-␦ is also induced by fasting (18) and physical exercise (19) , and it promotes the formation of highly oxidative skeletal muscle fibers (19) . Moreover, PPAR-␦ itself can increase expression of PGC-1␣ and lead to mitochondrial biogenesis and enhanced oxidative phosphorylation (3). The Gly482Ser substitution of PGC-1A has been linked to increased risk of diabetes (15, 20) , but no association of SNPs of PPARD with diabetes has been reported. The novel finding of our study was that SNPs of PPARD together with the Gly482Ser polymorphism of PGC-1A increased the risk of diabetes by 2.2-fold. Interestingly, acarbose prevented the progression from IGT to diabetes in subjects carrying one or both risk alleles of PPARD and PGC-1A (Table 2) . What could be the mechanisms via which acarbose modifies the effect of SNPs of PPARD and PGC-1A on the risk of diabetes? Postprandial hyperglycemia and high FFAs contribute to the production of reactive oxygen species (16, 21) , which increase mitochondrial mass, mainly by overexpression of nuclear respiratory factors and PGC-1␣ (22) . Both acarbose and PGC-1␣ have a protective effect on reactive oxygen species formation, either by alleviating postprandial hyperglycemia and high FFAs or by transcriptionally regulating the mitochondrial antioxidant defense system (23) . Thus, acarbose may interact with SNPs of PPARD and PGC-1A and reduce oxidative stress and the development of diabetes.
Whether the Gly482Ser substitution of PGC-1A is a functional variant remains unclear (24) . As determined with the Genomatix Program (availabe at http://www. genomatix.de), the binding sites for known transcription factors are not altered by this polymorphism. Similarly, SNPs of PPARD included in the present study did not cause alterations in transcription factor binding sites and did not affect RNA expression levels of PPAR-␦ in adipose tissue samples. It is possible, however, that above-mentioned polymorphisms of PGC-1A and PPARD are in strong LD with functional variants in these genes or in other genes nearby.
The simultaneous presence of the C allele of rs6902123 of PPARD and the Pro12Pro genotype of PPARG2 increased the risk of diabetes by 3.9-fold in the present study, suggesting a gene-to-gene interaction. Both PPAR-␦ and PPAR-␥2 are activated by PGC-1␣ (2,7) and seem to interfere with adipocyte differentiation (25) . However, the mechanisms explaining the interaction of PPARD and PPARG2 on the risk of diabetes remain to be determined.
The effects of the PPARD, PGC-1A, and PPARG2 polymorphisms on the risk of diabetes in the present study might be overestimated because of multiple comparisons causing type I error. The threshold of statistical significance after the Bonferroni correction (one phenotype: conversion to diabetes and six polymorphisms analyzed) is P ϭ 0.008. However, even after this adjustment, ORs for the conversion to diabetes were still mostly significant (P ϭ 0.006 -0.024, Table 2 ; P ϭ 0.001 for the risk alleles of PPARD and PPARG2).
In summary, we have shown for the first time that SNPs of PPARD together with the Gly482Ser polymorphism of PGC-1A and the Pro12Ala genotype of PPARG2 are associated with the risk of type 2 diabetes. Moreover, we have demonstrated that the treatment with acarbose was able to reduce the risk of diabetes in carriers of the risk genotypes in PPARD and PGC-1A.
